Eli Lilly And Stock Filter Stocks by Fundamentals
| LLY Stock | USD 821.67 5.09 0.62% |
Eli Lilly and fundamentals help investors to digest information that contributes to Eli Lilly's financial success or failures. It also enables traders to predict the movement of Eli Stock. The fundamental analysis module provides a way to measure Eli Lilly's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Eli Lilly stock.
Eli | Shares Owned by Institutions |
Eli Lilly ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Eli Lilly's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Eli Lilly's managers, analysts, and investors.Environmental | Governance | Social |
Eli Lilly Institutional Holders
Institutional Holdings refers to the ownership stake in Eli Lilly that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Eli Lilly's outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Eli Lilly's value.| Shares | Morgan Stanley - Brokerage Accounts | 2024-12-31 | 14.4 M | State Farm Mutual Automobile Ins Co | 2024-12-31 | 12.6 M | Wellington Management Company Llp | 2024-12-31 | 12.6 M | International Assets Investment Management, Llc | 2024-09-30 | 12.5 M | Norges Bank | 2024-12-31 | 10.9 M | Capital Research Global Investors | 2024-12-31 | 10.8 M | Bank Of America Corp | 2024-12-31 | 10 M | Northern Trust Corp | 2024-12-31 | 9.4 M | Capital Research & Mgmt Co - Division 3 | 2024-12-31 | 8.7 M | Lilly Endowment Inc | 2024-12-31 | 96.9 M | Vanguard Group Inc | 2024-12-31 | 74.2 M |
Eli Fundamentals
| Return On Equity | 0.84 | ||||
| Return On Asset | 0.15 | ||||
| Profit Margin | 0.24 % | ||||
| Operating Margin | 0.43 % | ||||
| Current Valuation | 795.62 B | ||||
| Shares Outstanding | 897.99 M | ||||
| Shares Owned By Insiders | 0.17 % | ||||
| Shares Owned By Institutions | 83.57 % | ||||
| Number Of Shares Shorted | 6.36 M | ||||
| Price To Earning | 54.92 X | ||||
| Price To Book | 53.93 X | ||||
| Price To Sales | 16.99 X | ||||
| Revenue | 45.04 B | ||||
| Gross Profit | 36.62 B | ||||
| EBITDA | 15.23 B | ||||
| Net Income | 10.59 B | ||||
| Cash And Equivalents | 2.07 B | ||||
| Cash Per Share | 2.97 X | ||||
| Total Debt | 33.64 B | ||||
| Debt To Equity | 1.58 % | ||||
| Current Ratio | 1.13 X | ||||
| Book Value Per Share | 15.81 X | ||||
| Cash Flow From Operations | 8.82 B | ||||
| Short Ratio | 1.72 X | ||||
| Earnings Per Share | 11.74 X | ||||
| Price To Earnings To Growth | 1.25 X | ||||
| Target Price | 1010.47 | ||||
| Number Of Employees | 47 K | ||||
| Beta | 0.34 | ||||
| Market Capitalization | 765.4 B | ||||
| Total Asset | 78.71 B | ||||
| Retained Earnings | 13.54 B | ||||
| Working Capital | 4.36 B | ||||
| Current Asset | 12.57 B | ||||
| Current Liabilities | 8.23 B | ||||
| Annual Yield | 0.01 % | ||||
| Five Year Return | 1.83 % | ||||
| Net Asset | 78.71 B | ||||
| Last Dividend Paid | 5.2 |
About Eli Lilly Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Eli Lilly and's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Eli Lilly using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Eli Lilly and based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.| ZLAB | Zai Lab | |
| ASLE | AerSale Corp | |
| ATS | AT S Austria |
Additional Tools for Eli Stock Analysis
When running Eli Lilly's price analysis, check to measure Eli Lilly's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Eli Lilly is operating at the current time. Most of Eli Lilly's value examination focuses on studying past and present price action to predict the probability of Eli Lilly's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Eli Lilly's price. Additionally, you may evaluate how the addition of Eli Lilly to your portfolios can decrease your overall portfolio volatility.